



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

21 June 2017  
EMA/CHMP/ICH/308817/2008  
Committee for Human Medicinal Products

## ICH guideline Q4B Annex 4B on evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on Tests for specified micro-organisms Step 5

Transmission to CHMP	June 2008
Transmission to interested parties	June 2008
Deadline for comments	September 2008
Final approval by CHMP	December 2008
Date for coming into operation	June 2009



# ICH guideline Q4B Annex 4B on evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on Tests for specified micro-organisms Table of contents

<b>1. Introduction .....</b>	<b>3</b>
<b>2. Q4B outcome .....</b>	<b>3</b>
2.1. Analytical procedures.....	3
2.2. Acceptance criteria .....	3
<b>3. Timing of annex implementation .....</b>	<b>3</b>
<b>4. Considerations for implementation.....</b>	<b>3</b>
4.1. General consideration .....	3
4.2. FDA consideration .....	3
4.3. EU consideration .....	3
4.4. MHLW consideration .....	4
4.5. Health Canada consideration.....	4
<b>5. References used for the Q4B evaluation .....</b>	<b>4</b>

## **1. Introduction**

This annex is the result of the Q4B process for Microbiological Examination of Non-Sterile Products: Tests for Specified Micro-organisms.

The proposed texts were submitted by the Pharmacopoeial Discussion Group (PDG).

## **2. Q4B outcome**

### ***2.1. Analytical procedures***

The ICH Steering Committee, based on the evaluation by the Q4B Expert Working Group (EWG), recommends that the official pharmacopoeial texts, Ph.Eur. 2.6.13. Microbiological Examination of Non-Sterile Products: Tests for Specified Micro-organisms, JP 4.05 Microbiological Examination of Non-Sterile Products: II. Microbiological Examination of Non-Sterile Products: Tests for Specified Micro-organisms, and USP <62> Microbiological Examination of Nonsterile Products: Tests for Specified Microorganisms can be used as interchangeable in the ICH regions.

### ***2.2. Acceptance criteria***

The proposed texts evaluated did not contain acceptance criteria.

## **3. Timing of annex implementation**

When this annex is implemented (incorporated into the regulatory process at ICH Step 5) in a region, it can be used in that region. Timing might differ for each region.

## **4. Considerations for implementation**

### ***4.1. General consideration***

When sponsors or manufacturers change their existing methods to the implemented Q4B-evaluated pharmacopoeial texts that are referenced in Section 2.1 of this annex, any change notification, variation, and/or prior approval procedures should be handled in accordance with established regional regulatory mechanisms pertaining to compendial changes.

### ***4.2. FDA consideration***

Based on the recommendation above, and with reference to the conditions set forth in this annex, the pharmacopoeial texts referenced in Section 2.1 of this annex can be considered interchangeable. However, FDA might request that a company demonstrate that the chosen method is acceptable and suitable for a specific material or product, irrespective of the origin of the method.

### ***4.3. EU consideration***

For the European Union, the monographs of the Ph. Eur. have mandatory applicability. Regulatory authorities can accept the reference in a marketing authorisation application, renewal or variation application citing the use of the corresponding text from another pharmacopoeia as referenced in Section 2.1, in accordance with the conditions set out in this annex, as fulfilling the requirements for

compliance with the Ph. Eur. Chapter 2.6.13. on the basis of the declaration of interchangeability made above.

#### **4.4. MHLW consideration**

The pharmacopoeial texts referenced in Section 2.1 of this annex can be used as interchangeable in accordance with the conditions set out in this annex. Details of implementation requirements will be provided in the notification by MHLW when this annex is implemented.

#### **4.5. Health Canada consideration**

In Canada any of the pharmacopoeial texts cited in Section 2.1 of this annex and used in accordance with the conditions set out in this annex can be considered interchangeable.

### **5. References used for the Q4B evaluation**

5.1 The PDG Stage 5B sign-off document:

Japanese Pharmacopoeial Forum, Volume 14, Number 4 (December 2005)

5.2 The pharmacopoeial references for Microbiological Examination of Non-Sterile Products: Tests for Specified Micro-organisms for this annex are:

5.2.1 European Pharmacopoeia (Ph. Eur.): 6.3 Edition (official on January 2009) Microbiological Examination of Non-Sterile Products: Tests for Specified Micro-organisms (reference 01/2009: 20613)

5.2.2 Japanese Pharmacopoeia (JP): 4.05 Microbiological Examination of Non-Sterile Products: II. Microbiological Examination of Non-Sterile Products: Tests for Specified Micro-organisms as it appears in Supplement I to the Japanese Pharmacopoeia Fifteenth Edition (September 28, 2007, The Ministry of Health, Labour and Welfare Ministerial Notification No. 316). The English version was published on January 9, 2008.

5.2.3 United States Pharmacopeia (USP): <62> Microbiological Examination of Nonsterile Products: Tests for Specified Microorganisms official in USP 30, January 2007.